Rebound exacerbation multiple sclerosis following cessation of oral treatment

被引：20

作者：

Beran, Roy G. ^{[1
,2
,3
,4
]}

Hegazi, Yaser ^{[1
,2
]}

Schwartz, Raymond S. ^{[5
]}

Cordato, Dennis J. ^{[1
,2
,5
]}

机构：

[1] Univ New S Wales, Liverpool Hosp, Dept Neurol, Sydney, NSW 2052, Australia

[2] Univ New S Wales, South Western Sydney Clin Sch, Sydney, NSW 2052, Australia

[3] Griffith Univ, Sch Med, Nathan, Qld 4111, Australia

[4] Strateg Hlth Evaluators, Northbridge, NSW 1560, Australia

[5] Southern Neurol, Kogarah, NSW, Australia

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2013年 / 2卷 / 03期

关键词：

Multiple sclerosis; Fingolimod; BG12; Rebound;

D O I：

10.1016/j.msard.2012.11.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: Multiple sclerosis (MS) management is changing, revolutionized by oral agents. Immune Reconstitution Inflammatory Syndrome (IRIS) describes exaggerated response to both exogenous (infective) and endogenous (non-infective) antigens. Methods: This paper reports two cases of MS "rebound" following withdrawal of oral treatments. Results: Two patients, with suboptimal response to interferons, trialled oral MS treatment (fingolimod and BG12) with excellent response. Upon cessation both experienced MS "rebound" which responded to steroids. Conclusions: "Rebound" may occur following withdrawal of oral MS therapies. Patients should be advised accordingly and possibly started on alternative treatment before the immunomodulating effect of therapy has subsided. (C) 2013 Published by Elsevier B.V.

引用

页码：252 / 255

页数：4

共 6 条

[1] A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis [J].

Kappos, Ludwig ;

Radue, Ernst-Wilhelm ;

O'Connor, Paul ;

Polman, Chris ;

Hohlfeld, Reinhard ;

Calabresi, Peter ;

Selmaj, Krzysztof ;

Agoropoulou, Catherine ;

Leyk, Malgorzata ;

Zhang-Auberson, Lixin ;

Burtin, Pascale .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) :387-401

[2] Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway [J].

Linker, Ralf A. ;

Lee, De-Hyung ;

Ryan, Sarah ;

van Dam, Anne M. ;

Conrad, Rebecca ;

Bista, Pradeep ;

Zeng, Weike ;

Hronowsky, Xiaoping ;

Buko, Alex ;

Chollate, Sowmya ;

Ellrichmann, Gisa ;

Brueck, Wolfgang ;

Dawson, Kate ;

Goelz, Susan ;

Wiese, Stefan ;

Scannevin, Robert H. ;

Lukashev, Matvey ;

Gold, Ralf .

BRAIN, 2011, 134 :678-692

[3] Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis [J].

Mehling, M. ;

Johnson, T. A. ;

Antel, J. ;

Kappos, L. ;

Bar-Or, A. .

NEUROLOGY, 2011, 76 (08) :S20-S27

[4] Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy [J].

Miravalle, Augusto ;

Jensen, Rikke ;

Kinkel, Philip .

ARCHIVES OF NEUROLOGY, 2011, 68 (02) :186-191

[5] Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis [J].

O'Connor, P. W. ;

Goodman, A. ;

Kappos, L. ;

Lublin, F. D. ;

Miller, D. H. ;

Polman, C. ;

Rudick, R. A. ;

Aschenbach, W. ;

Lucas, N. .

NEUROLOGY, 2011, 76 (22) :1858-1865

[6] Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab [J].

Wenning, Werner ;

Haghikia, Aiden ;

Laubenberger, Joerg ;

Clifford, David B. ;

Behrens, Peter F. ;

Chan, Andrew ;

Gold, Ralf .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (11) :1075-1080

← 1 →